Webinar video | Life Sciences Session #8: Global MAs and regulatory data protection a substantive and procedural challenge
During this session, our speakers Philippe de Jong and Kirian Claeyé will discuss the interesting judgment of the General Court in Polpharma v. EMA.
Our speakers will explain the judgment’s impact on whether a new medicinal product is entitled to a separate initial marketing authorisation, or belongs to the same global marketing authorisation as an earlier medicinal product. In other words, can the new medicinal product benefit from its own regulatory data protection period or not?
The judgment is furthermore not only interesting from a substantive point of view, but also contains some interesting examples on the pitfalls that may arise under EU procedural law in challenging decisions from the European Commission, whether in this area or others.
Recommended articles
Hospital mergers no longer subject to the Belgian Competition Authority’s prior review
The legislator has now had the last word, by providing that, in principle, hospital mergers are no longer subject to the BCA’s prior review and approval.
Read on
EU citizens rally for medical cannabis but face a rigid European Commission
In the EU, access to medical cannabis is a matter of national policy. A group of citizens wants to change that by leveraging a citizens’ initiative and prompting the European Commission to act.
Read on
WEBINAR VIDEO | Belgium’s medicines reimbursement reform
During this webinar, Kirian Claeyé and Bart Junior Bollen guide you through the eagerly anticipated reform of the reimbursement procedures for medicines in Belgium.
Read on